Article

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: A population-based study in routine clinical practice

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD 20882, USA.
The Lancet Oncology (Impact Factor: 24.69). 07/2011; 12(7):663-72. DOI: 10.1016/S1470-2045(11)70145-0
Source: PubMed

ABSTRACT

Concurrent testing for human papillomavirus (HPV) and cervical cytology (co-testing) is an approved alternative to cytology alone in women aged 30 years and older. We aimed to assess the safety in routine clinical practice of 3-year screening intervals for women testing negative for HPV with normal cytology and to assess if co-testing can identify women at high risk of cervical cancer or cervical intraepithelial neoplasia grade 3 (CIN3) or worse over 5 years.
We assessed the 5-year cumulative incidence, starting in 2003-05, of cervical cancer and CIN3 or worse for 331,818 women aged 30 years and older who enrolled in co-testing at Kaiser Permanente Northern California (Berkeley, CA, USA) and had adequate enrolment co-test results. Follow-up continued until Dec 31, 2009. We defined cumulative incidence to include prevalence at enrolment and incidence after enrolment. Prevalence at enrolment was defined as the ratio of women diagnosed with each outcome on the biopsy visit immediately after their enrolment screening visit to the total enrolled women. At screening visits only HPV test and Pap smear samples were collected, and at biopsy visits colposcopically directed biopsies were taken. To estimate post-enrolment incidence, we used Weibull survival models.
In 315,061 women negative by HPV testing, the 5-year cumulative incidence of cancer was 3.8 per 100,000 women per year, slightly higher than for the 306,969 who were both negative by HPV and Pap testing (3.2 per 100,000), and half the cancer risk of the 319,177 who were negative by Pap testing (7.5 per 100,000). 313,465 (99.5%) women negative by HPV testing had either normal cytology or equivocal abnormalities. Abnormal cytology greatly increased cumulative incidence of CIN3 or worse over 5 years for the 16,757 positive by HPV testing (12.1%vs 5.9%; p<0.0001). By contrast, although statistically significant, abnormal cytology did not increase 5-year risk of CIN3 or worse for women negative by HPV testing to a substantial level (0.86%vs 0.16%; p=0.004). 12,208 (73%) of the women positive by HPV testing had no cytological abnormality, and these women had 258 (35%) of 747 CIN3 or adenocarcinoma in situ, [corrected] 25 (29%) of 87 cancers, and 17 (63%) of 27 adenocarcinomas.
For women aged 30 years and older in routine clinical practice who are negative by co-testing (both HPV and cytology), 3-year screening intervals were safe because a single negative test for HPV was sufficient to reassure against cervical cancer over 5 years. Incorporating HPV testing with cytology also resulted in earlier identification of women at high risk of cervical cancer, especially adenocarcinoma. Testing for HPV without adjunctive cytology might be sufficiently sensitive for primary screening for cervical cancer.
Intramural Research Program of the US National Cancer Institute/NIH/DHHS, and the American Cancer Society.

Full-text preview

Available from: ncbi.nlm.nih.gov
    • "Primary hrHPV-based cervical cancer screening is an important scientific and clinical advance because it offers better reassurance of low cancer risk compared to cytology-only cervical cancer screening conducted at the same interval [11]. The effectiveness and safety of HPV-based primary cervical cancer screening has been assessed in large-scale randomized clinical trials performed in several European countries, Canada, and India1213141516171819202122232425 and in screening cohorts with longitudinal follow-up data from Europe and the United States2627282930313233343536373839. According to their results, hrHPV testing as a stand-alone test or in combination with cytology (co-testing) increases the sensitivity for detecting women with underlying cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN2+) and grade 3 or worse (CIN3+), provides better and longer protection against invasive cervical cancer, and reduces cervical cancer mortality compared to cytology testing alone [12,13,15,18,19,26,32,33,40,41]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Testing cervical smears for the presence of high-risk human papillomaviruses (hrHPV) increases the sensitivity for detecting women with underlying high-grade cervical intraepithelial neoplasia (CIN) and provides better and longer protection against invasive cervical cancer compared to cytology testing alone. The Abbott RealTime High Risk HPV test (RealTime) is a hrHPV DNA test with concurrent partial genotyping for HPV16 and HPV18 and aggregate detection of 12 other hrHPV types that have been extensively analytically and clinically evaluated over the last 6 years.
    No preview · Article · Nov 2015 · Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology
  • Source
    • "Second, we incorporated the findings from our work to better reflect the accuracy of colposcopy (Cantor et al, 2008). Third, if a woman had a Papanicolaou smear result of atypical squamous cells of undetermined significance (ASC-US) and a normal colposcopy result, we assumed that two additional follow-up visits over a 1-year period would also be required (Centers for Disease Control and Prevention, 2011; Katki et al, 2011). Fourth, the sensitivity and specificity for all screening and diagnostic tests were updated based on recently published studies (Goldie et al, 2004; Guillaud et al, 2006; Garner, 2014). "
    [Show abstract] [Hide abstract]
    ABSTRACT: DNA ploidy analysis involves automated quantification of chromosomal aneuploidy, a potential marker of progression toward cervical carcinoma. We evaluated the cost-effectiveness of this method for cervical screening, comparing five ploidy strategies (using different numbers of aneuploid cells as cut points) with liquid-based Papanicolaou smear and no screening. A state-transition Markov model simulated the natural history of HPV infection and possible progression into cervical neoplasia in a cohort of 12-year-old females. The analysis evaluated cost in 2012 US$ and effectiveness in quality-adjusted life-years (QALYs) from a health-system perspective throughout a lifetime horizon in the US setting. We calculated incremental cost-effectiveness ratios (ICERs) to determine the best strategy. The robustness of optimal choices was examined in deterministic and probabilistic sensitivity analyses. In the base-case analysis, the ploidy 4 cell strategy was cost-effective, yielding an increase of 0.032 QALY and an ICER of $18 264/QALY compared to no screening. For most scenarios in the deterministic sensitivity analysis, the ploidy 4 cell strategy was the only cost-effective strategy. Cost-effectiveness acceptability curves showed that this strategy was more likely to be cost-effective than the Papanicolaou smear. Compared to the liquid-based Papanicolaou smear, screening with a DNA ploidy strategy appeared less costly and comparably effective.British Journal of Cancer advance online publication, 28 April 2015; doi:10.1038/bjc.2015.95 www.bjcancer.com.
    Full-text · Article · Apr 2015 · British Journal of Cancer
  • Source
    • "From our findings, it has been proved that cytology triage with HR-HPV testing is more sensitive and specific than conventional cytology triage [6] [22]. HPV testing is an important ancillary diagnostic tool in identifying women who are at risk of progression to SIL, when the number of colposcopy referrals and follow-up tests [6] [22] decreases. For this reason, it is necessary to have validated molecular tests for the identification of viral antigens in biological samples, in order to Fig. 1. Results after 6 months. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human papillomavirus (HPV) has been recognized as the major etiologic agent of cervical squamous cell carcinoma. However, it has been demonstrated that HPV infection is usually a self-limited process and does not lead to significant epithelial lesions or cancer. Recent data indicate that persistent high-risk HPV (HR-HPV) infections have a significantly increased risk of developing incident high-grade cervical intraepithelial neoplasia and cervical cancer. Our aim, therefore, was to assess whether there exist HPV genotypes whose persistence can be considered powerful surrogates of a progressive disease. We retrospectively selected all patients with a negative cytological diagnosis or with atypical squamous cells of undetermined significance, with a positive test for HR-HPV, different from HPV types 16 and 18, and assessed the significance of the risk of progression based on the persistence of the specific HR-HPV. We retrospectively queried the database of our Colposcopy Clinic for all patients with a negative cytological diagnosis or with atypical squamous cells of undetermined significance and a positive test for HR-HPV, and we calculated the incidence of progression to lesions greater than or equal to low-grade squamous intraepithelial lesions after 6 months, according to the HPV type. A progression rate of 48.27% was found in patients tested positive for HPV-31 (Group 1), 38.46% in patients tested positive for HPV-45 (Group 2), and 5.73% in patients tested positive for HPV types other than HPV-16, HPV-18, HPV-31, and HPV-45 (Group 3). Our data demonstrate that the persistence of HPV-31 and HPV-45 is strongly associated with the occurrence of squamous intraepithelial lesion. Copyright © 2014. Published by Elsevier B.V.
    Full-text · Article · Dec 2014 · Taiwanese journal of obstetrics & gynecology
Show more